Article
Hematology
Karen Thudium Mueller, Stephan A. Grupp, Shannon L. Maude, John E. Levine, Michael A. Pulsipher, Michael W. Boyer, Keith J. August, G. Doug Myers, Constantine S. Tam, Ulrich Jaeger, Stephen Ronan Foley, Peter Borchmann, Stephen J. Schuster, Edmund K. Waller, Rakesh Awasthi, Bernd Potthoff, Andy Warren, Edward R. Waldron, Fraser McBlane, Andrea Chassot-Agostinho, Theodore W. Laetsch
Summary: The study shows that humoral and cellular immune responses to tisagenlecleucel did not affect clinical outcomes in pediatric and young adult B-ALL patients and adult DLBCL patients.
Article
Hematology
Richard T. Maziarz, Jie Zhang, Hongbo Yang, Xinglei Chai, Chengbo Yuan, Elisabeth Schwarz, Mihael Jakovac, Marcela Martinez-Prieto, Abhijit Agarwal, Evgeny Degtyarev, Constantine Tam, Gilles Salles
Summary: This study compares the efficacy of tisagenlecleucel with historical treatments for adults with r/r DLBCL, showing that tisagenlecleucel is associated with lower risk of death and higher overall response rate. The analysis supports improved response and overall survival in patients treated with tisagenlecleucel compared to historical treatments.
Article
Biochemistry & Molecular Biology
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, Jose Antonio Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andres Jose Maria Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thieblemont
Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.
Article
Biochemistry & Molecular Biology
Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, Pierre Sesques, Guillaume Manson, Guillaume Cartron, David Beauvais, Louise Roulin, Francois Xavier Gros, Marie Therese Rubio, Pierre Bories, Jacques Olivier Bay, Cristina Castilla Llorente, Sylvain Choquet, Rene-Olivier Casasnovas, Mohamad Mohty, Stephanie Guidez, Magalie Joris, Michael Loschi, Sylvain Carras, Julie Abraham, Adrien Chauchet, Laurianne Drieu La Rochelle, Benedicte Deau-Fischer, Olivier Hermine, Thomas Gastinne, Jean Jacques Tudesq, Elodie Gat, Florence Broussais, Catherine Thieblemont, Roch Houot, Franck Morschhauser
Summary: This study compared the efficacy and toxicity of Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). The results showed that axi-cel had better overall response rate, complete response rate, progression-free survival, and overall survival compared to tisa-cel. However, axi-cel also had higher frequency of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome compared to tisa-cel.
Article
Medicine, General & Internal
Michael J. Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, Tomasz Wrobel, Fritz Offner, Shang-Ju Wu, Guillaume Cartron, Mark Hertzberg, Anna Sureda, David Perez-Callejo, Linda Lundberg, James Relf, Mark Dixon, Emma Clark, Kathryn Humphrey, Martin Hutchings, Marek Trney
Summary: Glofitamab therapy is effective for DLBCL, but more than half of the patients experience grade 3 or 4 adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Jee H. Choe, Hisham Abdel-Azim, William Padula, Mohamed Abou-El-Enein
Summary: This study evaluated the cost-effectiveness of CAR-T cell therapies for relapsed or refractory DLBCL. The results showed that second-line axicabtagene ciloleucel and third-line or later tisagenlecleucel were cost-effective, but uncertainty remains.
Article
Oncology
Mariana Bastos-Oreiro, Ana de las Heras, Maria Presa, Miguel A. Casado, Carlos Pardo, Victoria Martin-Escudero, Anna Sureda
Summary: This study assessed the cost-effectiveness and cost-utility of axi-cel versus tisa-cel in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) from the perspective of the Spanish National Health System. The analysis showed that axi-cel is highly cost-effective when compared to tisa-cel in adult patients with relapsed/refractory DLBCL in Spain.
Article
Hematology
Gilles Salles, Stephen J. Schuster, Martin Dreyling, Luca Fischer, John Kuruvilla, Piers E. M. Patten, Bastian von Tresckow, Sonali M. Smith, Ana Jimenez-Ubieto, Keith L. Davis, Carla Anjos, Jufen Chu, Jie Zhang, Chiara Lobetti Bodoni, Catherine Thieblemont, Nathan H. Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Yucai Wang, Brian K. Link
Summary: The ELARA trial demonstrates that tisagenlecleucel (tisa-cel) is highly effective in treating relapsed or refractory follicular lymphoma (r/r FL). Compared to usual care, tisa-cel showed significantly higher complete response rate, overall response rate, and improved survival outcomes at 12 months.
Article
Immunology
Ying Ni, Lixia Gao, Yan Lu, Shiguang Ye, Lili Zhou, Wenbin Qian, Aibin Liang, Ping Li
Summary: This study found that patients with resolved HBV infection are at a moderate risk of developing HBV reactivation during BTKis treatment in relapsed or refractory DLBCL, but HBV infection does not affect the efficacy of BTKis treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Eva Gonzalez Barca
Summary: This article describes new promising therapies that are in clinical development to treat relapsed/refractory DLBCL, including CAR T-cell and monoclonal antibody therapies.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Immunology
Xianggui Yuan, Xian Li, Yurong Huang, Xueli Jin, Hui Liu, Aiqi Zhao, Weiping Zhang, Wenbin Qian, Yun Liang
Summary: This study evaluated the efficacy and safety of zanubrutinib plus salvage chemotherapy in R/R DLBCL patients and found that it showed high efficacy and manageable tolerability. Additionally, CAR-T cell therapy may be a priority strategy for poor responders to BTKi-based treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Gloria Iacoboni, Guillermo Villacampa, Nuria Martinez-Cibrian, Rebeca Bailen, Lucia Lopez Corral, Jose M. Sanchez, Manuel Guerreiro, Ana Carolina Caballero, Alberto Mussetti, Juan-Manuel Sancho, Rafael Hernani, Pau Abrisqueta, Carlos Solano, Anna Sureda, Javier Briones, Alejandro Martin Garcia-Sancho, Mi Kwon, Juan Luis Reguera-Ortega, Pere Barba
Summary: Tisagenlecleucel shows promising efficacy in treating R/R LBCL with a best ORR of 60% and CR of 32%, with a median response duration of 8.9 months. Treatment with tisa-cel in a European SOC setting demonstrates a manageable safety profile and durable complete responses for patients with LBCL.
Article
Oncology
Erin M. Hall, Dwight E. Yin, Rakesh K. Goyal, Atif A. Ahmed, Grace S. Mitchell, Shawn D. St Peter, Terrie G. Flatt, Ibrahim A. Ahmed, Weijie Li, Richard J. Hendrickson, Keith J. August, G. Doug Myers
Summary: Tisagenlecleucel has shown good efficacy in treating B-ALL patients, with the need for more intervention in handling efficacy and persistence issues. Proper management of patients with active infections may consider tisagenlecleucel as a potential treatment option.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Yvette L. Kasamon, Lauren S. L. Price, Olanrewaju O. Okusanya, Nicholas C. Richardson, Ruo-Jing Li, Lian Ma, Yu-Te Wu, Marc Theoret, Richard Pazdur, Nicole J. Gormley
Summary: Selinexor is a new potential treatment option for adult patients with relapsed or refractory diffuse large B-cell lymphoma, showing promising efficacy but also significant toxicities that require close monitoring and supportive care.
Article
Oncology
Boram Lee, Hyunwoo Lee, Junhun Cho, Sang Eun Yoon, Seok Jin Kim, Woong-Yang Park, Won Seog Kim, Young Hyeh Ko
Summary: Genetic mechanisms underlying treatment resistance in recurrent/refractory diffuse large B-cell lymphoma (rrDLBCL) were explored through targeted deep sequencing, identifying key gene mutations associated with resistance and potential candidate genes for future treatment strategies.
FRONTIERS IN ONCOLOGY
(2021)
